Apnimed
Cambridge, Massachusetts, United States · Healthcare, Manufacturing · 82 employees
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based
Funding history
- Funding Round — $150.0M — Mar 2026
- Funding Round — $35.0M — Oct 2025
- Funding Round — $23.0M — Sep 2025
- Funding Round — $16.5M — Apr 2025
- Series series c — $79.8M — Jan 2023
Recent signals
- Jun 08, 2026: Apnimed Inc. Appoints Kevin Lind as Chief Executive Officer
- Mar 27, 2026: Raised $150.0M
- Oct 01, 2025: Raised $35.0M
- Sep 24, 2025: Raised $23.0M
- Apr 25, 2025: Acquired Apnimed acquires global rights to sulthiame
- Apr 24, 2025: Raised $16.5M
- Oct 23, 2024: Apnimed, Inc. Appoints Ramzi Benamar as Chief Financial Officer
- Jan 22, 2024: Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
See plans & pricing → Track Apnimed’s funding, hiring, and signals — with verified contacts — on Fundz.